PRIMA BIOMED LTD | 0,049 Euro | +0,004 +8,89 % | |
| WKN: 541644 ISIN: AU000000PRR9 Ticker-Symbol: YP1 | Frankfurt | 24.05.13 | 17:28 Uhr |
Branche BiotechnologieAktienmarkt AUSTRALIEN |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 24.05. | PRIMA BIOMED LTD: Mailing of Prospectus and Entitlement and Acceptance Form | 1 | ASX | |
| 21.05. | Prima BioMed Ltd - 6-K, Report of foreign issuer | - | SEC Filings | |
| 20.05. | Prima BioMed to Present at the Second Annual Marcum LLP MicroCap Conference | 47 | Marketwired | |
| SYDNEY, AUSTRALIA -- (Marketwired) -- 05/20/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") has announced today that Matthew Lehman, its Chief Executive... Mehr lesen zu: Prima BioMed to Present at the Second Annual Marcum LLP MicroCap Conference | ||||
| 20.05. | PRIMA BIOMED LTD: Prima to present at Marcum LLP Microcap Conference | 1 | ASX | |
| 20.05. | PRIMA BIOMED LTD: Change of Director's Interest Notice | 1 | ASX | |
| 17.05. | Prima BioMed Ltd.: Mittelzufluss aus Aktienplatzierung in Höhe von 6,2 Mio. AUD zur Finanzierung weiterer klinischer Studien | 166 | dpa-AFX | |
| Prima BioMed Ltd.: Mittelzufluss aus Aktienplatzierung in Höhe
von 6,2 Mio. AUD zur Finanzierung weiterer klinischer Studien
DGAP-News: Prima BioMed Ltd. / Schlagwort(e): Sonstiges Prima BioMed
Ltd.:... Mehr lesen zu: Prima BioMed Ltd.: Mittelzufluss aus Aktienplatzierung in Höhe von 6,2 Mio. AUD zur Finanzierung weiterer klinischer Studien | ||||
| 17.05. | Prima BioMed Issues the Following Notice to Stockholders of the Company | 62 | Marketwired | |
| SYDNEY, AUSTRALIA -- (Marketwired) -- 05/16/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") has announced in pursuant to shareholder approval received... Mehr lesen zu: Prima BioMed Issues the Following Notice to Stockholders of the Company | ||||
| 17.05. | PRIMA BIOMED LTD: Cleansing Statement & Appendix 3B | - | ASX | |
| 16.05. | PRIMA BIOMED LTD: Results of Meeting | 2 | ASX | |
| 16.05. | PRIMA BIOMED LTD: EGM 2013 Chairman's Address | - | ASX | |
| 15.05. | Prima BioMed raises $5m from Share Purchase Plan | - | Proactive Investors | |
| 15.05. | PRIMA BIOMED LTD: Completion of SPP | - | ASX | |
| 14.05. | PRIMA BIOMED LTD: Entitlement Offer Letter to Shareholders | 6 | ASX | |
| 14.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2013 - 1 | 71 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 14.05.2013 CUM KAPITALMASSNAHME UND AM
15.05.2013 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 14.05.2013
AND EX CAPITAL... Mehr lesen zu: XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2013 - 1 | ||||
| 13.05. | Prima BioMed Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | |
| 13.05. | PRIMA BIOMED LTD: Entitlement Offer Prospectus & Appendix 3B | 6 | ASX | |
| 08.05. | Prima BioMed Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | |
| 08.05. | Prima BioMed erweitert Board of Directors | 66 | dpa-AFX | |
| Prima BioMed erweitert Board of Directors
DGAP-News: Prima BioMed Ltd. / Schlagwort(e): Personalie Prima
BioMed erweitert Board of Directors
08.05.2013 / 09:44
---------------------------------------------------------------------
Prima... Mehr lesen zu: Prima BioMed erweitert Board of Directors | ||||
| 08.05. | Russell J. Howard to Join Prima BioMed's Board of Directors | 58 | Marketwired | |
| SYDNEY, AUSTRALIA -- (Marketwired) -- 05/07/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that Russell J. Howard, PhD, will join... Mehr lesen zu: Russell J. Howard to Join Prima BioMed's Board of Directors | ||||
| 08.05. | PRIMA BIOMED LTD: Appendix 3X | 2 | ASX | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| ENTREMED | 1,351 | -1,46 % | EntreMed Reports First Quarter 2013 Financial Results |
| CELL THERAPEUTICS | 0,944 | -4,26 % | Possible Bearish Inside Day Candle Pattern Detected for Cell Therapeutics |
| STEMCELLS | 1,428 | +2 % | New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012 / Five Star Equities Provides Stock Research on NuPathe and StemCells |
| EACOM TIMBER | 0,233 | -0,43 % | Eacom Timber Corp: Eacom earns $1.55-million in Q1 |
| DISCOVERY LABORATORIES | 1,271 | 0 % | Discovery Labs Announces Completion of $14.25 Million Public Offering |
